Splicing machinery is impaired in rheumatoid arthritis, associated with disease activity and modulated by anti-TNF therapy

Autor: Antonio González, Chary López-Pedrera, Mª Angeles Aguirre, Raúl M. Luque, Rafaela Ortega Castro, Eduardo Collantes-Estevez, Nuria Barbarroja, Iván Arias de la Rosa, Carlos Perez-Sanchez, J. Calvo, A. M. Patiño-Trives, Carmen Conde, Alejandro Escudero-Contreras, M. D. C. Abalos-Aguilera, María Luque-Tévar, Mercedes del Rio-Moreno, Justo P Castano-Fuentes, Ricardo Blazquez-Encinas, P. Segui, Pilar Font, Cristóbal Román-Rodríguez, Sergio Pedraza-Arevalo, Alejandro Ibáñez-Costa
Rok vydání: 2021
Předmět:
Male
Neutrophils
tumor necrosis factor inhibitors
Fc receptor
Gene Expression
Cell Cycle Proteins
Anti-Citrullinated Protein Antibodies
Monocytes
Arthritis
Rheumatoid

Mice
RNA
Small Nuclear

Synovial Fluid
Immunology and Allergy
Lymphocytes
Cells
Cultured

biology
Serine-Arginine Splicing Factors
Anti–citrullinated protein antibody
RNA-Binding Proteins
Middle Aged
Ribonucleoproteins
Small Nuclear

DNA-Binding Proteins
biological therapy
Rheumatoid arthritis
Antirheumatic Agents
Cytokines
Tumor necrosis factor alpha
Female
RNA Splicing Factors
medicine.symptom
Antibody
Adult
Immunology
Inflammation
Rheumatoid Arthritis
General Biochemistry
Genetics and Molecular Biology

Proinflammatory cytokine
Ribonucleoprotein
U1 Small Nuclear

Rheumatology
medicine
Synovial fluid
Animals
Humans
Adaptor Proteins
Signal Transducing

business.industry
Sequence Analysis
RNA

Tumor Necrosis Factor-alpha
medicine.disease
Splicing Factor U2AF
Repressor Proteins
Alternative Splicing
Case-Control Studies
biology.protein
Spliceosomes
RNA
Citrullination
business
Zdroj: Annals of the Rheumatic Diseases
ISSN: 1468-2060
Popis: ObjectivesTo characterise splicing machinery (SM) alterations in leucocytes of patients with rheumatoid arthritis (RA), and to assess its influence on their clinical profile and therapeutic response.MethodsLeucocyte subtypes from 129 patients with RA and 29 healthy donors (HD) were purified, and 45 selected SM elements (SME) were evaluated by quantitative PCR-array based on microfluidic technology (Fluidigm). Modulation by anti-tumour necrosis factor (TNF) therapy and underlying regulatory mechanisms were assessed.ResultsAn altered expression of several SME was found in RA leucocytes. Eight elements (SNRNP70, SNRNP200, U2AF2, RNU4ATAC, RBM3, RBM17, KHDRBS1 and SRSF10) were equally altered in all leucocytes subtypes. Logistic regressions revealed that this signature might: discriminate RA and HD, and anti-citrullinated protein antibodies (ACPAs) positivity; classify high-disease activity (disease activity score-28 (DAS28) >5.1); recognise radiological involvement; and identify patients showing atheroma plaques. Furthermore, this signature was altered in RA synovial fluid and ankle joints of K/BxN-arthritic mice. An available RNA-seq data set enabled to validate data and identified distinctive splicing events and splicing variants among patients with RA expressing high and low SME levels. 3 and 6 months anti-TNF therapy reversed their expression in parallel to the reduction of the inflammatory profile. In vitro, ACPAs modulated SME, at least partially, by Fc Receptor (FcR)-dependent mechanisms. Key inflammatory cytokines further altered SME. Lastly, induced SNRNP70-overexpression and KHDRBS1-overexpression reversed inflammation in lymphocytes, NETosis in neutrophils and adhesion in RA monocytes and influenced activity of RA synovial fibroblasts.ConclusionsOverall, we have characterised for the first time a signature comprising eight dysregulated SME in RA leucocytes from both peripheral blood and synovial fluid, linked to disease pathophysiology, modulated by ACPAs and reversed by anti-TNF therapy.
Databáze: OpenAIRE